DuPont Decomposition

Why does MEDPLUS earn its ROE?

Breaking down Return on Equity into profitability, efficiency, and leverage.

ROE = Net Margin × Asset Turnover × Equity Multiplier

11.1% = 3.2% × 1.75 × 1.99

Latest: FY2026

Profitability

Net Margin

3.2%

2.5% →3.2%

How much profit per ₹ of revenue

Efficiency

Asset Turnover

1.75x

1.45x →1.75x

Revenue per ₹ of assets

Leverage

Equity Multiplier

1.99x

1.83x →1.99x

Assets funded by equity vs debt

Trend Analysis

ROE improved by 4.4 pp over 5 years. Driven by asset turnover improving (1.45x → 1.75x).

Historical Decomposition

Last 5 years

YearRevenuePATNet MarginAsset TOLeverageROE
FY20220Cr0Cr2.5%1.451.836.8%
FY20230Cr0Cr1.1%1.621.883.3%
FY20240Cr0Cr1.2%1.851.904.2%
FY20250Cr0Cr2.5%1.831.938.6%
FY20260Cr0Cr3.2%1.751.9911.1%

How to read DuPont

  • Rising ROE from margin = pricing power, operational improvement (good)
  • Rising ROE from turnover = better asset utilization (good)
  • Rising ROE from leverage = more debt, amplified risk (caution)
  • Falling ROE across all three = structural deterioration (red flag)

See DCF fair value for MEDPLUS

Combine financial quality with intrinsic value.

See Fair Value →

DuPont decomposition from audited annual financials. Factual analysis, not investment advice.

MEDPLUS DuPont Analysis — ROE 11.1% | YieldIQ